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Abstract
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), infects one third of the world’s population.
Among these infections, clinical isolates belonging to the W-Beijing appear to be emerging, representing about 50% of Mtb
isolates in East Asia, and about 13% of all Mtb isolates worldwide. In animal models, infection with W-Beijing strain, Mtb
HN878, is considered ‘‘hypervirulent’’ as it results in increased mortality and causes exacerbated immunopathology in
infected animals. We had previously shown the Interleukin (IL) -17 pathway is dispensable for primary immunity against
infection with the lab adapted Mtb H37Rv strain. However, it is not known whether IL-17 has any role to play in protective
immunity against infection with clinical Mtb isolates. We report here that lab adapted Mtb strains, such as H37Rv, or less
virulent Mtb clinical isolates, such as Mtb CDC1551, do not require IL-17 for protective immunity against infection while
infection with Mtb HN878 requires IL-17 for early protective immunity. Unexpectedly, Mtb HN878 induces robust production
of IL-1b through a TLR-2-dependent mechanism, which supports potent IL-17 responses. We also show that the role for IL-
17 in mediating protective immunity against Mtb HN878 is through IL-17 Receptor signaling in non-hematopoietic cells,
mediating the induction of the chemokine, CXCL-13, which is required for localization of T cells within lung lymphoid
follicles. Correct T cell localization within lymphoid follicles in the lung is required for maximal macrophage activation and
Mtb control. Since IL-17 has a critical role in vaccine-induced immunity against TB, our results have far reaching implications
for the design of vaccines and therapies to prevent and treat emerging Mtb strains. In addition, our data changes the
existing paradigm that IL-17 is dispensable for primary immunity against Mtb infection, and instead suggests a differential
role for IL-17 in early protective immunity against emerging Mtb strains.
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Introduction
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis
(TB), infects one third of the world’s population. While most
infected individuals develop latent TB, 5–10% of infected
individuals develop active TB. In addition, although most infected
people with latent TB remain asymptomatic, they have ,10%
lifetime risk of developing into active TB. Among these infections,
clinical isolates being typed as belonging to the W-Beijing strain
appear to be increasingly prevalent. In fact, recent reports show
that W-Beijing family Mtb strains represent about 50% of Mtb
isolates in East Asia, and are believed to account for at least 13%
of all Mtb isolates worldwide [1–4]. More importantly, multiple
studies have identified that W-Beijing strains are over-represented
among drug resistant isolates [5,6], and are significantly associated
with human immunodeficiency virus (HIV) infection in humans
[7]. In animal models, infection with Mtb HN878 isolate, the best
studied of the W-Beijing isolates, is thought to be ‘‘hypervirulent’’
as it results in increased mortality and causes severe immunopa-
thology in infected animals [8,9]. In addition, studies suggest that
M.bovis Bacille Calmette-Guerin (BCG) vaccination may be less
protective against W-Beijing genotype Mtb strains [4], thus
contributing to its successful recent worldwide emergence.
The immune responses that mediate protective immunity
against Mtb infection are through the production of proinflamma-
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tory cytokines such as Interferon gamma (IFN-c) and Tumor
necrosis factor alpha (TNF-a), both cytokines that activate
macrophages to mediate Mtb control. This is consistent with the
finding that Mtb HN878 infection in mice induces a Type I
Interferon response, which limits the generation of T helper type 1
cells (Th1), that produce IFN-c and TNF-a [9,10]. In addition,
Mtb HN878 infection also inhibits the production of TNF-a in
macrophages [11], suggesting that the increased virulence of Mtb
HN878 infection may be due to the reduced generation of Th1
responses and impaired macrophage activation in the host.
Interleukin-17 (IL-17) is a pro-inflammatory cytokine, well
described for its role in host defense against extracellular bacterial
pathogens [12]. We had previously shown that the IL-17 pathway
is not required for primary immunity against infection with the lab
adapted strain, Mtb H37Rv [13–15]. However, it is not known
whether IL-17 has any role to play in protective immunity against
infection with clinical Mtb isolates. In the current study, we tested
whether IL-17 is required for protective immunity following
infection with the hypervirulent Mtb HN878, and the less virulent
Mtb CDC1551 clinical isolates. Surprisingly, we found that while
lab adapted Mtb isolates such as Mtb H37Rv, or less virulent Mtb
clinical isolates such as Mtb CDC1551, did not require IL-17 for
early protective immunity against infection, infection with Mtb
HN878 required the production of IL-17 for protective immunity.
Our data suggest that the dependence on IL-17 to drive protective
immunity against Mtb HN878 is due to the differential ability of
Mtb HN878 to induce high levels of IL-1b through a TLR-2-
dependent mechanism, resulting in high IL-17 production. In
addition, our data show that the role for IL-17 in mediating early
protective immunity against Mtb HN878 is through IL-17 receptor
(IL-17R) signaling in non-hematopoietic cells, to induce expression
of the chemokine, CXCL-13. CXCL-13 expression attracts
cytokine-producing CXCR5+ T cells which localize near Mtb-
infected macrophages, to form lung lymphoid follicles for optimal
macrophage activation and Mtb control. Our novel results suggest
that the protective immune requirements for emerging hypervir-
ulent Mtb isolates are likely different from the requirements for lab
adapted and less virulent Mtb isolates, and thus need to be studied
independently as demonstrated here. As recent work has
demonstrated a critical role for IL-17 in vaccine induced immunity
against TB [16,17], our results have far reaching implications for
the design of vaccines and therapies to prevent and treat emerging
Mtb strains such as W-Beijing strains.
Materials and Methods
Mtb infection in mice
B6 (B6), IL-172/2 [18], IL17RA2/2 (IL-17R2/2) [19],
CXCR52/2 [20], IL-17GFP reporter, IL-1R2/2, TLR22/2
and ESAT-6 T-Cell Receptor (TCR) Transgenic (Tg) mice [21]
were bred at the Children’s Hospital of Pittsburgh or purchased
from Jackson lab. ESAT-6 TCR Tg mice were also crossed to the
CXCR52/2 mice to generate Tg mice which were deficient in
CXCR5. Experimental mice were age- and sex-matched and used
between the ages of 6 to 8 wks. Mtb strains H37Rv, CDC1551 or
HN878 were cultured in Proskauer Beck medium containing
0.05% Tween 80 to mid-log phase and frozen in 1 ml aliquots at
270uC. Mice were aerosol infected with ,100 CFU of bacteria
using a Glas-Col airborne infection system [16]. At given time
points, organs were harvested, homogenized and serial dilutions of
tissue homogenates plated on 7H11 plates and CFU determined.
In some experiments, adenovirus over-expressing IL-17 or control
adenovirus expressing luciferase vector was delivered once
(56108 pfu) intratracheally.
Ethics statement
All mice were used in accordance following the National
Institutes of Health guidelines for housing and care of laboratory
animals and in accordance with University of Pittsburgh
Institutional Animal Care and Use Committee guidelines and
were approved under Protocol 0807913. All efforts were made to
minimize suffering and pain as described in this approved
protocol.
Lung cell preparation and flow cytometry
Lung cell suspensions were prepared as described [16] and
single cell suspensions were stained with appropriate fluoro-
chrome-labeled specific antibodies or isotype control antibodies.
Cells were collected using a Becton Dickinson FACS Aria flow
cytometer using FACS Diva software. Cells were gated based on
their forward by side scatter characteristics and the frequency of
specific cell types was calculated using FlowJo (Tree Star Inc,
CA).
Detection of IFN-c and IL-17 producing cells by ELISpot
assay
ESAT-61–20-specific IFN-c and IL-17-producing IA
b-restricted
T cells from infected lungs or spleen were enumerated using
peptide-driven ELISpot as described [22]. Briefly, 96 well ELISpot
plates were coated with monoclonal anti-mouse IFN-c or IL-17,
blocked with media containing 10% FBS. Cells from lungs and
spleen were seeded at an initial concentration of 56105 cells/well
and subsequently diluted two fold. Irradiated B6 splenocytes were
used as APCs at a concentration of 16106 cells/well in the
presence of ESAT-61–20 (10 mg/ml) peptide and IL-2 (10 U/ml).
After 24 hrs, plates were washed and probed with biotinylated
anti-mouse IFN-c or IL-17. Spots were visualized and enumerated
using a CTL-Immunospot S5 MicroAnalyzer. No spots were
detected in cultures lacking antigen or when using cells from
uninfected mice.
Author Summary
Mycobacterium tuberculosis (Mtb), the causative agent of
tuberculosis (TB), infects one third of the world’s popula-
tion. Among these infections, clinical isolates belonging to
the W-Beijing are emerging, representing about 50% of
Mtb isolates in East Asia, and about 13% of all Mtb isolates
worldwide. In animal models, infection with W-Beijing
strain, Mtb HN878, is considered ‘‘hypervirulent’’ resulting
in increased mortality. The proinflammatory cytokine
Interleukin (IL)-17 is thought to be dispensable for primary
immunity against Mtb infection. We report here that while
IL-17 is dispensable for protection against infection with
lab adapted Mtb strains such as H37Rv, or less virulent Mtb
clinical isolates such as Mtb CDC1551, IL-17 is required for
early protective immunity against Mtb HN878 infection.
The dependence on IL-17 to drive protective immunity
against Mtb HN878 is due to the differential ability to
induce high levels of IL-1b through a TLR-2-dependent
mechanism, driving potent IL-17 responses, induction of
the chemokine CXCL-13 and localization of T cells within
lung lymphoid follicles for maximal macrophage activation
and Mtb control. Together, our data change the existing
paradigm that IL-17 is dispensable for primary immunity
against Mtb infection, and suggests a differential require-
ment for IL-17 in protective immunity against some
emerging Mtb strains.
IL-17 Is Required for Hypervirulent Mtb Infection
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Bone marrow-derived macrophages and dendritic cell
preparation
BMDMs and BMDCs were generated from the bone marrow of
B6 or gene deficient mice. Cells were extracted from femurs and
16107 cells were plated with 10 ml of cDMEM supplemented
with 20 ng/mL mouse recombinant GM-CSF (Peprotech). Cells
were cultured for 3 days at 37uC in 5% CO2, after which an
additional 10 ml of cDMEM containing 20 ng/ml rmGM-CSF
was added. On day 7, non-adherent cells were collected by
centrifugation and counted as DCs, while adherent cells were
collected and used as BMDMs. Lung or BMDCs were treated with
Mtb HN878 or Mtb H37Rv components, such as whole cell lysate,
cell wall or lipids preparations (20 mg/ml each, BEI Resources,
obtained under National Institutes of Health [NIH] contract AI-
75320)
Lung dendritic cell purification
Single cell suspensions from DNAse/collagenase-treated lung
tissue were prepared as previously described. CD11c+ cells were
isolated using magnetic anti-CD11c beads (Miltenyi Biotec Inc.),
according to the manufacturer’s instructions.
In vitro Mtb infection
BMDCs and lung dendritic cells prepared as previously
described were plated at a density of 16106 cells/ml and rested
overnight. Cells were subsequently infected with different Mtb
strains at a multiplicity of infection (MOI) of 5 for BMDCs or 0.1
for lung dendritic cells in antibiotic-free DMEM, for 24 hrs,
following which total lung cell suspensions from B6 or gene
deficient mice were added in a 1:1 ratio to the infected dendritic
cells, and co-cultured for 6 days.
Generation of ESAT-6- Tg Th17 cells
Naive CD4+ T cells were isolated from single cell suspensions
generated from lymph nodes and spleens of ESAT-6 TCR Tg
mice using a positive CD4 T cell isolation kit (Miltenyi Biotech) as
described [23]. For generation of Th17 cells, cells were cultured in
Complete Iscove’s medium containing TGFb (5 ng/ml), IL-6
(30 ng/ml), IL-23 (50 ng/ml), anti-IL-4 (10 mg/ml), anti-IFN-c
(10 mg/ml), and IL-2 (10 U/ml) and APCs [24]. T cells were
incubated for six days at 37uC and 5% CO2 and supplemented
with an equivalent volume of media containing IL-2 (10 U/ml) on
day 3. Cells were harvested on day 6 and washed twice with PBS.
For adoptive transfer, 3–56106 ESAT-6 TCR Tg Th17 cells were
transferred intravenously into recipient mice, following which mice
were rested for 24 hours and challenged with Mtb H37Rv by the
aerosol route.
Generation of bone marrow chimeric mice
To generate chimeric mice, mice were given a medicated
Sulfa-Trim diet containing 1.2% sulfamethoxazole and 0.2%
trimethoprim (TestDiet) two weeks prior to irradiation. Mice were
sub-lethally irradiated with 1000 rads in two doses (X-Rad 320).
Mice were subsequently reconstituted with 106106 bone marrow
cells from B6 or gene deficient mice via i.v. injection. Mice were
allowed to reconstitute for 45 days while continuing to receive a
Sulfa-Trim and acidified water diet following which they were
used in experimental procedures.
Immunohistochemistry
Lung lobes were instilled with 10% neutral buffered formalin
and embedded in paraffin. Lung sections were stained with
hematoxylin and eosin (H&E) and inflammatory features were
evaluated by light microscopy (Research Histology Core, Univer-
sity of Pittsburgh). For immunofluorescent staining, formalin-fixed
lung sections were cut, immersed in xylene to remove paraffin and
then hydrated in 96% alcohol and PBS. Antigens were unmasked
with a DakoCytomation Target Retrieval Solution and non-
specific binding was blocked with 5% (v/v) normal donkey serum
and Fc block (BD Pharmingen, San Diego, CA). Endogenous
biotin (Sigma Aldrich) was neutralized by adding first avidin,
followed by incubation with biotin. Sections were probed with
anti-B220 to detect B cells (Clone RA3-6B2, BD Pharmingen, San
Diego, CA), anti-CD3 to detect T cells (Clone M-20, Santa Cruz
Biotechnology, Santa Cruz, CA), anti-CXCL13 (Clone143614, R
& D Biosystems) to detect CXCL-13 expression, and inducible
NO synthase (goat anti-mouse, M-19; Santa Cruz Biotechnology)
and F4/80 (MCA497GA, Serotec) to detect activated macro-
phages within inflammatory lesions. B cell lymphoid follicles were
outlined with the automated tool of the Zeiss Axioplan 2
microscope (Carl Zeiss) and total area and average size was
calculated in squared microns. F4/80 macrophages expressing
iNOS in five random 206 fields were enumerated per lung (n = 5
lungs) and the average was calculated. 3–5 granulomas per lobe in
each group were randomly chosen to quantify CXCL13 mRNA
expression in 2006 fields as described before [17]. Samples were
analyzed in a blinded fashion.
In situ hybridization
Paraffin embedded tissue sections were deparaffinized and
washed in ethanol. Stringent in situ hybridization (50uC with 0.1M
DTT in the hybridization mix) was performed with 35S-labeled
riboprobes as previously described [20]. Tissue sections were
coated with NTB emulsion (Carestream/Kodak), exposed at 10uC
for 14 days, counterstained with hematoxylin (Vector Laborato-
ries) and mounted with Permount (Fisher). Images were visualized
using an Olympus BX41 microscope (Olympus) and captured
using a SPOT RT3 digital camera (Diagnostics Instruments).
Protein estimation by ELISA
Protein levels for cytokines and chemokines in culture super-
natants, serum or lung homogenates were measured using a mouse
Luminex assay (Linco/Millipore).
Statistical analysis
Differences between the means of groups were analyzed using
the two tailed Student’s t-test in GraphPad Prism 5 (La Jolla, CA).
Results
IL-17 is dispensable for early protective immunity against
lab strain Mtb H37Rv, but required for protective
immunity against the hypervirulent clinical isolate, Mtb
HN878
We had previously shown that IL-23 deficient mice (IL-232/2)
[13] and mice lacking IL-17 signaling (IL-17RA2/2) [14,15] are not
more susceptible than C57BL/6J mice (B6) mice, to low dose Mtb
H37Rv aerosol infection. However, it is not known if the IL-17
pathway is required for protective immunity against infection with
clinical isolates such as the hypervirulent Mtb HN878 strain. Thus,
we aerosol infected B6 or mice lacking IL-17A (IL-172/2), with low
doses of either Mtb H37Rv or Mtb HN878 and determined the effect
of IL-17 deficiency on bacterial burden in the lungs. As previously
published with IL-17RA2/2 mice [14,15], we found that the IL-
172/2 mice are not more susceptible than B6 mice to low dose
aerosol Mtb H37Rv infection, at either early or later time points
IL-17 Is Required for Hypervirulent Mtb Infection
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(Fig. 1A). Interestingly, when IL-172/2 mice were infected with low
doses of hypervirulent Mtb HN878 infection, we found that
IL-172/2 mice exhibited increased lung bacterial burden in the
lungs at both early and later time points (Fig. 1B). To further test if
this requirement for IL-17 in mediating protective immunity against
clinical Mtb isolates was limited to Mtb HN878, or if IL-17 was
required for protection against other clinical isolates, we infected B6
or IL-172/2 mice with the less virulent clinical isolate Mtb
CDC1551, and determined bacterial burden in the lungs. We
found that similar to Mtb H37Rv infection, IL-17 was not required
for protective immunity against Mtb CDC1551 infection, since IL-
172/2 mice exhibited comparable lung bacterial burden to B6
infected mice at both early and late time points (Fig. 1C). These data
demonstrate for the first time that IL-17 is required for protective
immunity against specific clinical Mtb isolates such as Mtb HN878,
but not Mtb lab strains such as Mtb H37Rv, or less virulent clinical
isolates such as Mtb CDC1551.
Mtb HN878 infection induces potent IL-17 responses
when compared to Mtb H37Rv infection
Our data suggest that IL-17 is required for early protective
immunity following infection with Mtb HN878, but not Mtb
H37Rv in mice. Thus, we next addressed if infection with Mtb
H37Rv and HN878 induced different levels of IL-17 production in
the lung. We found that lung IL-17 protein levels were
significantly elevated in B6 mice infected with Mtb HN878, when
compared to levels of IL-17 in lungs of B6 mice infected with Mtb
H37Rv (Fig. 2A). In addition, when IL-17 reporter GFP mice were
infected with similar low doses of either Mtb H37Rv or Mtb
HN878, we found that Mtb HN878 infection induced a higher
frequency and total number of IL-17-producing cells in the
infected lungs (Fig. 2B–D). In addition, we found that the majority
of the lung IL-17+ cells were CD3+ T cells (Fig. 2E). Furthermore,
we found that increased numbers of Mtb antigen-specific ESAT61–
Figure 1. IL-17 is required for protective immunity against Mtb HN878 infection. B6 or IL-172/2 mice were aerosol infected with ,100 cfu
Mtb H37Rv (a), Mtb HN878 (b) or Mtb CDC1551 (c). Lung bacterial burden was determined by plating on D30 or D60 post-infection. The data points
represent the mean (6SD) of values from 3–5 samples. *p#0.05, ***p#0.0005, ns-not significant.
doi:10.1371/journal.ppat.1004099.g001
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20 IL-17-producing cells were detected in Mtb HN878-infected
lungs, when compared to Mtb H37Rv-infected lungs (Fig. 2F). In
contrast, no significant differences were observed in the number of
ESAT-6–specific IFN-c-producing cells in the lungs of B6 mice
infected with either Mtb HN878 or Mtb H37Rv (Fig. 2G).
Differentiation of Th17 cells is dependent on instructive signals
provided by APCs, thus we infected lung CD11c+ cells in vitro
with the two strains of Mtb, and subsequently co-cultured them
with naı¨ve lung cells for 6 days. Increased levels of IL-17 were
detected in Mtb HN878-infected co-culture supernatants, when
compared to levels detected in supernatants from Mtb
H37Rv-infected co-cultures (Fig. 2H). These data together suggest
that Mtb HN878 strain induces higher levels of IL-17 production
in lung cells, when compared to Mtb H37Rv infection.
Enhanced IL-17 production following Mtb HN878
infection is TLR-2 and IL-1b dependent
In order to define the mechanism driving enhanced IL-17
production during Mtb HN878 infection, we analyzed induction of
polarizing cytokines by lung DCs following infection with Mtb
H37Rv and Mtb HN878. We found increased IL-1b levels in
supernatants of lung DCs infected with Mtb HN878 strain, but not
Figure 2.Mtb HN878 induces potent IL-17 responses in infected mice. B6 mice were either aerosol infected with,100 cfu Mtb H37Rv or Mtb
HN878. Lungs were homogenized in saline on D30 post-infection and IL-17 protein levels were determined by Luminex (a). IL-17 GFP reporter mice
were aerosol infected with ,100 cfu Mtb H37Rv or Mtb HN878. The frequency (b) and absolute number (c) of lung IL-17-producing cells (GFP+) was
determined by flow cytometry at D25 post-infection. Representative flow cytometry histograms of lung cell suspensions from uninfected (Un), Mtb
H37Rv or Mtb HN878-infected IL-17 GFP reporter mice is shown (d). The number of CD3+IL-17+ lung cells was determined by flow cytometry (e). The
percentage of ESAT-61–20-specific, IL-17 (f) and IFN-c (g) producing cells in the lungs of these mice was determined by ELISpot assay. 1610
6 lung
CD11c+ cells from B6 mice and infected in vitro with Mtb H37Rv or Mtb HN878 (MOI 0.01). Subsequently, naı¨ve B6 total lung cell suspensions were
added to the culture, and 6 days later, IL-17 levels were determined in supernatants by ELISA (h). The data points represent the mean (6SD) of values
from 3–5 samples. *p#0.05, **p#0.005, ***p#0.0005. ns-not significant.
doi:10.1371/journal.ppat.1004099.g002
IL-17 Is Required for Hypervirulent Mtb Infection
PLOS Pathogens | www.plospathogens.org 5 May 2014 | Volume 10 | Issue 5 | e1004099
Figure 3. Mtb HN878-driven IL-17 production is dependent on TLR-2 and IL-1b. 16106 lung DCs from B6 mice were infected in vitro with
Mtb H37Rv or Mtb HN878 (MOI 0.01) for 48 h and IL-1b production was determined in the supernatants (a). 16106 B6 DCs were infected with Mtb
H37Rv or Mtb HN878 (MOI 0.01), following which naı¨ve B6 or IL-1R2/2 total lung cell suspensions were added to the culture, and IL-17 levels were
determined by ELISA on day 6 of the co-culture (b). B6 or IL-1R2/2 mice were aerosol infected with ,100 cfu Mtb HN878 and lung bacterial burden
was determined on D30 post-infection (c). The number of ESAT-61–20-specific, IL-17-producing cells in the lungs of uninfected (Un), Mtb HN878-
infected B6 and IL-1R2/2 mice was determined by ELISpot assay (d). 16106 BMDCs were treated in vitro with whole cell lysate, cell wall extract or a
lipid extract (20 mg/ml) of Mtb H37Rv or Mtb HN878, and IL-1b production in cell culture supernatants was determined by ELISA (e). 16106 lung
CD11c+ cells from B6 or TLR-22/2 mice and infected in vitro with Mtb H37Rv or Mtb HN878. Subsequently, naı¨ve B6 or TLR-22/2 total lung cell
suspensions were added to the culture, and IL-1b (f) and IL-17 (g) levels were determined by ELISA. The data points represent the mean (6SD) of
values from 3–5 samples. *p#0.05, **p#0.005, ***p#0.0005. nd-not detected.
doi:10.1371/journal.ppat.1004099.g003
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Mtb H37Rv (Fig. 3A). IL-1b has a critical role in IL-17 production
[25]. Importantly, when lung DCs were infected with Mtb HN878,
and IL-1R2/2 lung cells were co-cultured with infected DCs, IL-
17 production was significantly impaired in culture supernatants
(Fig. 3B), demonstrating that IL-17 production is IL-1b pathway
dependent. To confirm our in vitro findings in vivo during Mtb
infection, we infected B6 or IL-1R2/2 mice with low doses of
aerosolized Mtb HN878 and found that IL-1R2/2 mice had
significantly higher bacterial burden (Fig. 3C), and this coincided
with significantly reduced induction of Mtb-specific IL-17-produc-
ing T cells (Fig. 3D). Together, these data demonstrate that Mtb
HN878-driven IL-17 production is IL-1b dependent, both in vitro
and in vivo.
To further define the mechanism underlying IL-1b induction by
Mtb HN878, we incubated bone marrow derived DCs (BMDCs)
with different subcellular preparations from Mtb and found that
treatment with Mtb HN878 whole cell lysates and cell wall
extracts, but not lipids from Mtb HN878, induced IL-1b in
BMDCs (Fig. 3E). Given that TLR-2 recognizes cell wall
components from Mtb [26], and that its activation has been linked
to IL-1b production [27], we next determined whether IL-1b and
IL-17 production were dependent on activation through TLR-2.
We found that Mtb HN878-infection of TLR-22/2 lung DCs, had
a dramatic impairment in IL-1b production when compared to
infection of B6 DCs (Fig. 3F), and coincided with low IL-17
production in DC: lung cell co-cultures (Fig. 3G). These data
together suggest that when compared to Mtb H37Rv infection, Mtb
HN878 infection induces higher levels of IL-1b production in
APCs through a TLR-2-dependent mechanism, and this drives
increased IL-17 production.
IL-17 mediates protection against Mtb HN878 infection
by driving CXCL-13 induction, lung lymphoid follicle
formation and macrophage activation
IL-17 is well documented to drive the production of molecules
such as Keratinocyte chemoattractant (KC), and Granulocyte
Colony Stimulating Factor (G-CSF) to mediate neutrophil
recruitment and accumulation [12]. However, we did not find
any defects in total lung neutrophil numbers and lung neutrophil
accumulation within granulomas of B6 or IL-172/2 Mtb HN878
infected mice (data not shown). In addition, we did not find any
differences in pulmonary levels of KC and G-CSF in B6 and IL-
172/2 Mtb HN878 infected mice (data not shown). These data
together suggest the role for IL-17 in protective immunity against
Mtb HN878 infection is not mediated through its well documented
role in neutrophil recruitment. Since IL-17 can drive the induction
of Th1 responses in some intracellular pulmonary bacterial
infection models [28,29], we next determined if there were any
defects in generation of Th1 immune responses. Interestingly, we
did not find any differences in the accumulation of IFN-c (Fig.
S1A) or TNF-a-producing (Fig. S1B) Mtb-specific T cells in the
lungs of B6 and IL-17R2/2 Mtb HN878-infected mice. In
addition, we also found comparable numbers of activated CD4+
T cells accumulating in the Mtb HN878-infected B6 and
IL-17R2/2 lungs (Fig. S1C), including total IFN-c (Fig. S1D)
and IL-2-producing T cells (Fig. S1E). These data suggest that the
generation and accumulation of activated Th1 responses are not
defective in mice deficient in the IL-17 pathway.
We have recently described a role for early vaccine-induced IL-
17 in mediating CXCL-13 expression which resulted in localiza-
tion of CXCR5+ cytokine producing T cells near Mtb-infected
macrophages, an event crucial for optimal Mtb control [30]. The
correct localization of T cells expressing CXCR5 within the lung
parenchyma, results in formation of ectopic lymphoid structures,
which is required for activation of infected macrophages for
control of Mtb [30]. Thus, we next addressed whether the
increased susceptibility in IL-172/2 mice infected with Mtb
HN878 was due to defects in T cell localization near Mtb-infected
macrophages within the lung. We found that IL-172/2 mice
infected with Mtb HN878 exhibited increased lung perivascular T
cuffing (Fig. 4A), and this coincided with poorly formed lymphoid
follicles within the lungs of IL-172/2 Mtb HN878-infected mice,
when compared to B6 Mtb HN878-infected mice (Fig. 4B).
Importantly, this coincided with decreased accumulation of
activated iNOS-producing macrophages within the IL-172/2
Mtb HN878-infected lung inflammatory lesions, when compared
to the B6 Mtb HN878-infected lesions (Fig. 4C). To exclude a
direct effect of IL-17 on macrophage activation and Mtb control,
bone marrow macrophages (BMDMs) from B6 mice were infected
with Mtb HN878 and treated with either IFN-c or IL-17, or both
cytokines. Although we found that IL-17 treatment induced some
iNOS production in uninfected macrophages, it did not enhance
iNOS production in Mtb HN878-infected macrophages or
enhance control of Mtb in infected macrophages (Fig. S2A–B).
As expected, IFN-c treatment resulted in increased iNOS
production by macrophages and improved bacterial control, when
compared to untreated macrophages or IL-17 treated Mtb-infected
macrophages (Fig. S2A–B). Instead, we found that coincident with
reduced lymphoid follicle formation in IL-172/2 Mtb HN878-
infected lungs, expression of CXCL-13 mRNA expression within
lung lymphoid follicles was also reduced (Fig. 4D). These data
together suggest that following Mtb HN878 infection, enhanced
IL-17 production driven by the infection, plays a role in induction
of CXCL-13, localization of cytokine producing T cells near Mtb-
infected macrophages, and Mtb control.
Overexpression of IL-17 restores protective immunity in
IL-172/2 mice challenged with Mtb HN878
Our data show that IL-17 is required for protective immunity
against Mtb HN878 infection by mediating correct T cell
localization near Mtb-infected macrophages for optimal macro-
phage activation. We therefore tested if over expression of IL-17
by adenoviral vectors would rescue the increased susceptibility
observed in IL-172/2 Mtb HN878 infected mice. Thus, IL-172/2
Mtb HN878 infected mice received a single intratracheal delivery
of either adenovirus expressing a luciferase control vector or
adenovirus expressing IL17. We found that IL-17 overexpression
reversed the increased bacterial burden seen in IL-172/2 Mtb
HN878 infected mice (Fig. 5A), resulted in decreased T cell
perivascular cuffing (Fig. 5B,C), improved formation of lung
lymphoid follicles (Fig. 5D), and coincident increase in CXCL-13
mRNA expression (Fig. 5e) and CXCL-13 protein (Fig. 5F), within
B cell lymphoid follicles in the lung. As a result, IL-17
overexpression resulted in increased accumulation of iNOS-
expressing macrophages within the inflammatory lesions
(Fig. 5G). To further confirm that CXCL-13 expression is critical
for localization of CXCR5-expressing Th1 cells within the
lymphoid follicles and Mtb control, we infected CXCR52/2 mice
with Mtb HN878. We found that CXCR52/2 mice exhibited
increased bacterial burden when compared to B6 Mtb HN878
infected mice (Fig. 6A). Importantly, we found that CXCR52/2
Mtb infected mice demonstrated enhanced T cell perivascular
cuffing (Fig. 6B) and this coincided with reduced formation of
lymphoid follicles (Fig. 6C), measured by determining the average
area of B cell follicle within the lungs of B6 and CXCR52/2 mice.
In addition, we found that the impaired localization of T cells
within the lung parenchyma resulted in decreased accumulation of
iNOS-producing macrophages (Fig. 6D), within the lung inflam-
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Figure 4. IL-17 mediates control of Mtb HN878 through CXCL13 induction, lymphoid follicle formation and macrophage activation.
B6 and IL-172/2 mice were aerosol infected with ,100 cfu Mtb HN878 and lungs were harvested on D60 post-infection. Pulmonary histology was
assessed on formalin-fixed, paraffin embedded lung sections that were stained with H&E (a). Arrows depict T cell perivascular cuffing. Serial sections
from infected lungs were also processed for immunofluorescence using antibodies specific for CD3 and B220 (b) or iNOS and F4/80 (c), and stained
for CXCL13 mRNA expression by in situ hybridization (d). 4006magnification for immunofluorescence images. Arrows within (d) indicate CXCL-13
mRNA expression. The average size of T cell perivascular cuffing (a) and B cell lymphoid follicles (b) was calculated using the morphometric tool of the
Zeiss Axioplan microscope. The number of iNOS-expressing cells per field (c) was counted and shown. n = 5–9 mice per group. ***p#0.005.
doi:10.1371/journal.ppat.1004099.g004
IL-17 Is Required for Hypervirulent Mtb Infection
PLOS Pathogens | www.plospathogens.org 8 May 2014 | Volume 10 | Issue 5 | e1004099
matory lesions, suggesting sub-optimal activation of macrophages
for Mtb control. In order to mechanistically address if presence of
Th17 cells could rescue the increased susceptibility seen in IL-
172/2 mice, we adoptively transferred Mtb-specific Th17 cells
generated from wild type ESAT-6 TCR Tg mice or from
CXCR52/2 ESAT-6 TCR Tg mice, into IL-172/2 mice which
were then infected with aerosolized Mtb HN878. Consistent with a
role for IL-17 in mediating protection against Mtb HN878 control,
adoptive transfer of wild type Th17 cells significantly reduced the
bacterial burden (Fig. 6E). In contrast, adoptive transfer of Th17
cells derived from CXCR52/2 mice did not decrease lung
bacterial burden (Fig. 6E). These data together conclusively
provide evidence that IL-17 expression during Mtb HN878
infection is required for effective induction of CXCL-13, a
chemokine that is key to facilitating productive interactions
between cytokine producing CXCR5-expressing T cells and
Mtb-infected macrophages for optimal Mtb HN878 control in
the lung.
IL-17R expression on non-hematopoietic cells is crucial
for mediating protective immunity against Mtb HN878
infection
IL-17R is primarily expressed on non-hematopoietic cells, but
IL-17R can also be expressed on hematopoietic cells such as
macrophages and dendritic cells [12]. Thus, we next addressed if
IL-17R signaling on hematopoietic or non-hematopoietic cells was
essential for inducing CXCL-13 expression and mediating
protection against Mtb HN878 infection. Thus, we generated
hematopoietic IL-17R2/2 bone marrow chimeric (BMC) mice (B6
host/2/2 BM) or non-hematopoietic IL-17R2/2 BMC mice
(2/2 host/B6 BM) and infected with Mtb HN878. As expected
based on our data, complete IL-17R2/2 BMC mice (2/2
host/2/2 BM) were more susceptible to Mtb HN878 infection
than complete B6 BMC mice (B6 host/B6 BM) (Fig. 7A), and
demonstrated defects in T cell localization (Fig. 7B), formation of
lymphoid follicles and CXCL-13 mRNA expression (Fig. 7C), and
CXCL-13 protein expression within B cell lymphoid follicles
(Fig. 7D). Interestingly, non-hematopoietic, but not hematopoietic
IL-17R2/2 BMC mice had increased lung bacterial burden
(Fig. 7A), and this coincided with increased perivascular T cell
cuffing (Fig. 7B) and reduced CXCL-13 mRNA and protein
expression (Fig. 7C,D). These data clearly demonstrate that IL-17
signaling in non-hematopoietic cells is required for CXCL-13
induction, to mediate correct T cell localization near Mtb infected
macrophages to confer protective immunity against Mtb HN878
infection.
Discussion
The Mtb isolate HN878, belongs to the W-Beijing family of
isolates, which have been associated with outbreaks throughout the
world, and with clusters of drug-resistant disease in the United
States [31]. W-Beijing strains have significant clinical relevance
because they are over-represented among drug resistant Mtb
isolates, and are associated with HIV infection in humans [7]. In
animal models, infection is considered hypervirulent due to
increased immunopathology and mortality [8]. In the current
paper, we show that IL-17 is required for early protective
immunity against Mtb HN878 infection, but not lab adapted
Mtb isolates such as H37Rv, or less virulent Mtb clinical isolates
such as CDC1551. Our data also suggest that the dependence on
IL-17 to drive early protective immunity against Mtb HN878 is
due to the differential ability of Mtb HN878 to induce high levels
of IL-17 production, through an IL-1b-TLR-2 dependent
pathway. Thus, defining the differential immune requirements
that mediate protective immunity against clinical isolates such as
the widely spreading W-Beijing isolate, is critical for successful
design of vaccines against emerging strains of Mtb. Thus, our novel
results demonstrating a role for IL-17 in primary immunity to
specific Mtb strains, have far reaching implications for the future
design of vaccines and therapies to prevent and treat TB
worldwide, especially emergent strains of clinical relevance for
public health.
Early studies using animal models showed that infection with
Mtb HN878 induced Type I interferons, and this coincided with
decreased induction of proinflammatory cytokines such as TNF-a,
IFN-c and IL-2, reduced T cell activation and increased
susceptibility to infection [8,10,11]. The hypervirulent phenotype
of Mtb HN878 was initially linked to production of phenolic
glycolipids (PGL), one of the major lipid components of the
mycobacterial cell wall, that could be mediating the inhibition of
protective Th1 responses [8,10,11]. Interestingly, when PGL was
expressed in Mtb H37Rv, a strain normally devoid of PGL
synthesis, it did not lead to increased virulence in infected mice
and rabbits, suggesting that PGLs in concert with other bacterial
factors likely mediates the hypervirulence of W-Beijing Mtb strains
[32]. Furthermore, it has been recently shown that PGL enhances
infectivity through CCR2-mediated TLR-independent recruit-
ment of permissive macrophages at the earliest stages of infection,
suggesting the presence of PGL in Mtb HN878 as a likely factor
contributing to the increased transmission of Mtb HN878 [33]. In
contrast, in the current study, we show that DCs infected with Mtb
HN878 are stimulated likely by a cell wall component that binds
TLR2, and triggers the secretion of IL-1b. In addition, the
increased induction of IL-1b in infected DCs mediates the
induction of IL-17 production, primarily in CD3+ T cells.
Accordingly, our studies show that in the presence of low IL-17
induction following Mtb H37Rv infection, absence of IL-17 as
shown here, or absence of IL-17R as published before [14,15],
does not impact protective immunity. In contrast, consistent with
the increased induction of IL-17 seen in Mtb HN878 infected
lungs, IL-17 is required for early protective immunity against
infection with Mtb HN878. Our data also show that a protective
role for IL-17 is not observed for all clinical Mtb isolates, as IL-
172/2 mice infected with the less virulent clinical isolate Mtb
CDC1551, does not show early increased susceptibility to
infection. Our data described here has tested the early protective
role for IL-17 in Mtb infection, and future studies determining
whether IL-17 is required for maintenance of Mtb control during
chronic stages of Mtb infection will be important. Without doubt,
future studies focused on defining whether specific lineages of Mtb
require IL-17 for protective immunity in acute and chronic Mtb
infection will be critical for successful vaccine design for global TB
control, by tailoring more specific strategies for prevalent emerging
strains of Mtb in certain geographical areas.
Our recent work has put forth the new ‘‘working hypothesis’’
that a protective TB granuloma in the lung is predominantly
composed of lymphoid follicles, where T cells and B cells are
strategically positioned near infected macrophages to form
lymphoid follicles or optimal activation to control Mtb infection
[17,20]. IL-17 induces expression of CXCL-13 in the lung and
mediates generation of lymphoid follicles following inflammation
[17,34]. Consistent with this newly described role for IL-17 in
driving formation of lymphoid follicles in the lung, our data show
that IL-172/2 mice which were more susceptible to Mtb HN878
infection have significant defects in T cell localization and
formation of lung lymphoid follicles within TB granulomas. In
addition, we found that the poorly formed lymphoid follicles with
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Figure 5. Adenoviral IL-17 overexpression reverses the increased susceptibility to Mtb HN878 infection in IL-172/2 mice. B6 or
IL-172/2 mice were aerosol infected with ,100 cfu Mtb HN878 and were either infected with a vector control adenovirus expressing luciferase
(Adluc) or with an adenoviral vector overexpressing IL-17 (AdIL-17) on day 9. Lung bacterial burden was determined on D30 post-Mtb infection (a).
Pulmonary histology was assessed on formalin-fixed, paraffin embedded lung sections that were stained with H&E (b). 1006magnification for H&E
sections. The average size of T cell perivascular cuffing (c) and B cell lymphoid follicles (d) was calculated using the morphometric tool of the Zeiss
Axioplan microscope. CXCL13 mRNA expression in formalin fixed, paraffin embedded lung sections was studied by in situ hybridization (e). 1006
magnification, arrows indicate areas of CXCL-13 mRNA expression. The area occupied by CXCL13 signal by in situ hybridization per 2006 field was
calculated using the morphometric tool of the Zeiss Axioplan microscope. Serial sections from infected lungs were also processed for
immunofluorescence using antibodies specific for CXCL13 and B220 (f). 4006magnification. Immunofluorescence staining was also performed using
antibodies specific for or iNOS and F4/80 and the numbers of iNOS+ cells were counted (g). 4006magnification. The data points represent values
from n = 5 mice per group. *p#0.05, **p#0.005, ***p#0.0005, ns-not significant.
doi:10.1371/journal.ppat.1004099.g005
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Figure 6. CXCR5 deficiency increases susceptibility to Mtb HN878 infection. B6 and CXCR52/2 mice were aerosol infected with ,100 cfu
Mtb HN878 and lung bacterial burden was determined on D30 post-infection (a). Pulmonary histology was assessed on formalin-fixed, paraffin
embedded lung sections. The average size of T cell perivascular cuffing (b) and B cell lymphoid follicles (c) was calculated using the morphometric
tool of the Zeiss Axioplan microscope. Serial sections from infected lungs were also processed for immunofluorescence using antibodies specific for
CD3 and B220 (c) or iNOS and F4/80 (d). The number of iNOS-expressing cells per field (d) was counted and shown. 4006magnification. Wild type or
CXCR52/2 ESAT-6 TCR Tg CD4+ T cells were in vitro differentiated to the Th17 subset and 26106 Th17 cells were adoptively transferred into IL-172/2
mice and then infected with low doses of Mtb HN878. Lung bacterial burden was determined on D30 post-infection (e). The data points represent
values from n = 5 mice per group. **p#0.005, ***p#0.0005.
doi:10.1371/journal.ppat.1004099.g006
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the lungs of IL-172/2 mice exhibited reduced induction of
CXCL13 mRNA and protein. Our data show that IL-172/2 Mtb
HN878-infected lungs accumulate similar numbers of proinflam-
matory T cells producing IFN-c, IL-2 and TNF-a, suggest that the
increased susceptibility to infection is not due to defects in
generation, or accumulation of proinflammatory T cells in the
lung, but due to defects in localization of cytokine-producing T
cells within lymphoid follicles to mediate macrophage activation.
The fact that overexpression of IL-17 using adenoviral vectors can
reverse the increased susceptibility, CXCL-13 expression, T cell
localization and lymphoid follicle formation within the IL-172/2
Mtb HN878-infected lung, further supports and validates this
hypothesis. However, it is also possible that absence of IL-17
impacts the generation and accumulation of B cells or other T cells
such as CD8+ T cells to mediate formation of B cell lymphoid
follicles, and should be addressed in future studies. IL-17R2/2
mice infected with Mtb H37Rv exhibit a transient early defect in
lymphoid follicle formation, coinciding with absence of a role for
IL-17 pathway in mediating protection [15]. These data together
suggest that following infection with Mtb HN878, IL-17 has a non-
redundant and prominent role to play in induction of CXCL-13
expression, likely through its effects on non-hematopoietic cells
such as epithelial cells and fibroblasts. This is consistent with the
ability of IL-17 to drive CXCL-13 expression in fibroblasts in vitro
[15]. Interestingly, both CXCL-13 and CXCR52/2 mice are
equally susceptible to infection with either Mtb H37Rv [20,23] or
Mtb HN878 described here, implicating IL-17-independent
pathways in CXCL-13 induction during Mtb H37Rv infection.
Further studies delineating and characterizing common versus
differential protective correlates across different Mtb lineages will
be necessary in designing vaccines, specific for clinical strains that
are endemic in different geographical locations of the world.
Our recent studies using CXCR52/2 mice in Mtb H37Rv
infection model, have demonstrated that expression of CXCR5 is
required for T cell localization within the lung and macrophage
activation for Mtb control [20]. Importantly, we showed that
adoptive transfer of CD4+ T cells expressing CXCR5 into Mtb
H37Rv-infected CXCR52/2 mice, was sufficient to allow T cells
to localize within the lung, reverse generation of lymphoid tissues
and improve disease outcome [20]. Consistent with these recent
findings, we report here that CXCR52/2 mice when infected with
Mtb HN878 are also susceptible to Mtb HN878 infection,
demonstrate defects in localization of T cells, formation of
lymphoid follicles and activation of macrophages within TB
granulomas. Importantly, IL-172/2 mice that receive Mtb-specific
Th17 cells expressing CXCR5, could reverse the increased
susceptibility and associated disease phenotype, but adoptive
transfer of Mtb-specific CXCR52/2 Th17 cells could not rescue
the disease phenotype in IL-172/2 Mtb HN878-infected mice.
These data together mechanistically provide evidence that
following Mtb HN878 infection, cytokine producing CD4+ T cells
express CXCR5 and respond to signals from IL-17-dependent
CXCL-13 to localize within the lung parenchyma to form
lymphoid follicles, and activate macrophages for Mtb control.
IL-17 is generally thought to be required for protective
immunity against extracellular pathogens, by inducing chemokines
that drive neutrophil recruitment for pathogen control [12]. Thus,
it was not surprising that early studies demonstrated that IL-17
was not required for protective immunity against intracellular
pathogen such as Mycobacteria [13,14,35], Listeria [14] and
Salmonella infections [36]. However, more recent work by us and
others has demonstrated that in some models of intracellular
infections, IL-17 is required for protective immunity to drive the
induction of IL-12 and generate Th1 responses [28,29]. In
contrast, the more widely appreciated role for IL-17 in TB, is its
role in mediating vaccine-induced protection against Mtb chal-
lenge [16,17]. Accordingly, targeting IL-17 to improve vaccine
design for TB is an active avenue of research [37]. Thus, our new
data demonstrating that the IL-17 pathway also plays a role in
primary immunity following infection with Mtb HN878, signifi-
cantly changes the existing paradigm that IL-17 is not required for
primary immunity against TB. Interestingly, some human studies
report increased IL-17 in active TB patients [38,39], while other
studies report increased IL-17 in latent TB patients [40,41] and
healthy controls [41,42], suggesting IL-17 may be associated with
either inflammation or protection, respectively. Thus, differential
IL-17 expression by some emerging Mtb strains may define the
final role for IL-17 in protection or pathology during TB, and
needs to be carefully studied.
In summary, data presented here demonstrates that IL-17 has
an early protective role to play in immunity against Mtb HN878
infection, by mediating induction of chemokines, T cell localiza-
tion within lymphoid follicle for macrophage activation and Mtb
control. These results demonstrate a novel and previously
undescribed role for IL-17 in primary immunity to TB, especially
considering that W-Beijing strains such as Mtb HN878 are
emerging as major drug resistant Mtb strains that are not protected
by prior BCG vaccination. Thus, targeting IL-17 to improve
vaccine stategies for protection against emerging Mtb strains such
as W-Beijing Mtb strains, may prove critical in controlling global
TB burdens.
Supporting Information
Figure S1 IL-17R2/2 mice have unaltered Th1 respons-
es. B6 or IL-17R2/2 mice were aerosol infected with ,100 cfu
Mtb HN878 and lungs were collected on D30 post-infection. The
percentage of ESAT-61–20-specific, IFN-c (a) and TNF-a (b)-
producing cells in the lungs of Mtb-infected mice and uninfected
mice (Un) was determined by Mtb-specific ELISpot assay. The
total number of activated lung CD4+ T cells (CD3+CD4+CD44+)
(c) that produced IFN-c (d) or IL-2 (e) was determined by flow
cytometry. The data points represent values from n = 3–5 mice per
group *p#0.05, **p#0.005, ***p#0.0005. ns-not significant.
(TIF)
Figure S2 IL-17 does not directly mediate macrophage
activation and Mtb control. BMDMs were in vitro infected
Figure 7. IL-17R expression on non-hematopoietic cells is required for protective immunity against Mtb HN878. Hematopoietic IL-
17R2/2 BMC mice (B6 host/2/2 BM), non-hematopoietic IL-17R2/2 BMC mice (2/2 host/B6 BM), complete IL-17R2/2 BMC mice (2/2 host/2/2BM)
and complete B6 BMC mice (B6 host/B6 BM) were generated as described under methods. BMC mice were aerosol infected with,100 cfu Mtb HN878
and lung bacterial burden was determined on D30 post-infection (a). Pulmonary histology was assessed on formalin-fixed, paraffin embedded lung
sections that were stained with H&E and the average size of T cell perivascular cuffing was calculated using the morphometric tool of the Zeiss
Axioplan microscope (b). T cell perivascular cuffing is indicated by the arrows. CXCL13 mRNA expression in formalin fixed, paraffin embedded lung
sections was studied by in situ hybridization (c). 1006magnification, arrows point to typical areas of CXCL13 mRNA expression. The area occupied by
CXCL13 signal by in situ hybridization per 2006 field was calculated using the morphometric tool of the Zeiss Axioplan microscope. Serial sections
from infected lungs were also processed for immunofluorescence using antibodies specific for CXCL13 and B220 (d). 4006magnification. The data
points represent values from n = 3–5 mice per group. *p#0.05, **p#0.005.
doi:10.1371/journal.ppat.1004099.g007
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with Mtb HN878 (MOI 5) and treated in the presence of IL-17,
IFN-c or both cytokines, and macrophage-mediated killing was
determined by bacterial plating of macrophage lysates (a). Nitrite
production by these macrophages in culture supernatants was
determined by using Griess reaction (b). The data points represent
the mean (6SD) of values from 3–5 samples. ***p#0.0005. ns-not
significant.
(TIF)
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